News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF

Epigenomics AG: Results from Microsimulation Model to be presented at renowned health conference

Berlin (Germany) and San Diego, CA (U.S.A.), October 2, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that Dr. Elvira D’Andrea, MD, MPH, one of the authors of the microsimulation model for comparing outcomes of colorectal cancer screening methods, including the Epi proColon® blood test, will present a summary of the results at the 12th European Public Health Conference of the European Public Health Association on November 21, 2019. At the conference, held in Marseille (France), Dr. D’Andrea, a modeling expert from Harvard Medical School, will present on “Quantifying the impact of adherence to screening on colorectal cancer incidence and mortality”. Adherence to testing is a critical element for the improvement of screening rates, and blood-based testing holds promise for the approximately 35% of eligible people not being screened regularly.

Epigenomics forges ahead with the publication in a scientific journal and will continue to keep its stakeholders informed on the progress of this process.

 

About colorectal cancer (CRC)
Colorectal cancer remains a leading cause of cancer death in the United States. Although screening and early detection of colorectal cancer can save lives, about 35% of eligible U.S. patients are not being screened regularly. The unscreened population disproportionately results in 43% of new colorectal cancer cases and about 76% of colorectal cancer deaths and costs. Approximately $18 billion is spent annually on this preventable disease. Over $13 billion is spent on cases from unscreened individuals.
By increasing screening and detecting more cancers early, the costs and deaths from this disease both can be addressed.

 

About Epi proColon®
Epi proColon® is indicated for colorectal cancer screening in average-risk patients who are unwilling or unable to perform colorectal cancer screening by colonoscopy and stool-based methods. It is a qualitative, in vitro diagnostic blood test for CRC that uses real-time PCR to detect methylation of a target DNA sequence within the Septin 9 gene promoter; methylation of this DNA sequence is associated with the occurrence of CRC and can be detected in cell-free DNA that circulates in the plasma.
For patients, the test only requires a simple blood sample draw as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.
Epi proColon is recipient of the 2019 Excellence in Molecular Diagnostics by Corporate LiveWire’s Innovation and Excellence Awards.
For more information on Epi proColon, visit www.epiprocolon.com.

 

About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung® and HCCBloodTest, blood-based tests for lung and liver cancer detection, has received CE mark in Europe.

 

Contact Epigenomics AG
Frederic Hilke
IR.on AG
Phone: +49 221 9140 970
ir@epigenomics.com

Contact in the USA
David Bull
Director of Marketing Tel: +1 240.912.6430
David.Bull@Epigenomics.com

 

Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.